Trial Profile

A Phase 1, Open-Label, Single Dose, Ethnobridging Study Evaluating the Safety, Tolerability and Pharmacokinetics of Lasofoxifene in Healthy Japanese and Caucasian Women

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jan 2023 New trial record
08 Dec 2022 According to a Sermonix Pharmaceuticals media release, data from the trial will be presented at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research - Translating Knowledge into Practice. The PK data are currently being analyzed and will be presented at the conference.
08 Dec 2022 According to a Sermonix Pharmaceuticals media release, a total of 16 women (eight Caucasian and eight Japanese) women have been enrolled in the trial till date.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com